Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Laura Dickinson

Showing results (31-40 of 52) with videos related to

Pageof 6
Sort By:
Antimicrobial Agents and Chemotherapy|July 22, 2015
Plasma Tenofovir, Emtricitabine, and Rilpivirine and Intracellular Tenofovir Diphosphate and Emtricitabine Triphosphate Pharmacokinetics following Drug Intake CessationLaura Dickinson, H Manisha Yapa, Akil Jackson, et al.
Antimicrobial Agents and Chemotherapy|November 13, 2013
Population pharmacokinetic and pharmacogenetic analysis of nevirapine in hypersensitive and tolerant HIV-infected patients from MalawiLaura Dickinson, Masautso Chaponda, Daniel F Carr, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|October 12, 2016
Brief Report: Pharmacokinetic/Pharmacodynamic Investigation of Single-Dose Oral Maraviroc in the Context of HIV-1 Pre-exposure ProphylaxisJulie Fox, Juan M Tiraboschi, Carolina Herrera, et al.
The Journal of Antimicrobial Chemotherapy|May 17, 2024
Tenofovir, emtricitabine, lamivudine and dolutegravir concentrations in plasma and urine following drug intake cessation in a randomized controlled directly observed pharmacokinetic trial to aid point-of-care testingLaura J Else, Laura Dickinson, Stacey Edick, et al.
The Journal of Antimicrobial Chemotherapy|October 1, 2008
Population pharmacokinetics of ritonavir-boosted saquinavir regimens in HIV-infected individualsLaura Dickinson, Marta Boffito, David J Back, et al.
Journal of Evaluation in Clinical Practice|August 12, 2024
The CONECT-6 case-finding tool to identify patients with complex needs: A few tips to promote understandingÉmilie Angrignon-Girouard, Charlotte Schwarz, Dana Howse, et al.
The European Respiratory Journal|June 17, 2017
A longitudinal modelling study estimates acute symptoms of community acquired pneumonia recover to baseline by 10 daysDaniel G Wootton, Laura Dickinson, Henry Pertinez, et al.
Tuberculosis (Edinburgh, Scotland)|June 15, 2017
Assessment of treatment response by colony forming units, time to culture positivity and the molecular bacterial load assay compared in a mouse tuberculosis modelGerjo J de Knegt, Laura Dickinson, Henry Pertinez, et al.
Plos One|January 23, 2026
Pharmacokinetics of Dolutegravir, nucleoside analogues, and intracellular metabolites using plasma separation cards: A comparative analysis with traditional sampling methods in healthy volunteersBeth Thompson, Laura J Else, Laura Dickinson, et al.
The Journal of Antimicrobial Chemotherapy|May 16, 2021
Pharmacokinetic/pharmacodynamic investigation of raltegravir with or without lamivudine in the context of HIV-1 pre-exposure prophylaxis (PrEP)Carolina Herrera, Julianne Lwanga, Ming Lee, et al.
Pageof 6

Showing results (31-40 of 52) with videos related to

Sort By:
Pageof 6
Antimicrobial Agents and Chemotherapy|July 22, 2015
Plasma Tenofovir, Emtricitabine, and Rilpivirine and Intracellular Tenofovir Diphosphate and Emtricitabine Triphosphate Pharmacokinetics following Drug Intake CessationLaura Dickinson, H Manisha Yapa, Akil Jackson, et al.
Antimicrobial Agents and Chemotherapy|November 13, 2013
Population pharmacokinetic and pharmacogenetic analysis of nevirapine in hypersensitive and tolerant HIV-infected patients from MalawiLaura Dickinson, Masautso Chaponda, Daniel F Carr, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|October 12, 2016
Brief Report: Pharmacokinetic/Pharmacodynamic Investigation of Single-Dose Oral Maraviroc in the Context of HIV-1 Pre-exposure ProphylaxisJulie Fox, Juan M Tiraboschi, Carolina Herrera, et al.
The Journal of Antimicrobial Chemotherapy|May 17, 2024
Tenofovir, emtricitabine, lamivudine and dolutegravir concentrations in plasma and urine following drug intake cessation in a randomized controlled directly observed pharmacokinetic trial to aid point-of-care testingLaura J Else, Laura Dickinson, Stacey Edick, et al.
The Journal of Antimicrobial Chemotherapy|October 1, 2008
Population pharmacokinetics of ritonavir-boosted saquinavir regimens in HIV-infected individualsLaura Dickinson, Marta Boffito, David J Back, et al.
Journal of Evaluation in Clinical Practice|August 12, 2024
The CONECT-6 case-finding tool to identify patients with complex needs: A few tips to promote understandingÉmilie Angrignon-Girouard, Charlotte Schwarz, Dana Howse, et al.
The European Respiratory Journal|June 17, 2017
A longitudinal modelling study estimates acute symptoms of community acquired pneumonia recover to baseline by 10 daysDaniel G Wootton, Laura Dickinson, Henry Pertinez, et al.
Tuberculosis (Edinburgh, Scotland)|June 15, 2017
Assessment of treatment response by colony forming units, time to culture positivity and the molecular bacterial load assay compared in a mouse tuberculosis modelGerjo J de Knegt, Laura Dickinson, Henry Pertinez, et al.
Plos One|January 23, 2026
Pharmacokinetics of Dolutegravir, nucleoside analogues, and intracellular metabolites using plasma separation cards: A comparative analysis with traditional sampling methods in healthy volunteersBeth Thompson, Laura J Else, Laura Dickinson, et al.
The Journal of Antimicrobial Chemotherapy|May 16, 2021
Pharmacokinetic/pharmacodynamic investigation of raltegravir with or without lamivudine in the context of HIV-1 pre-exposure prophylaxis (PrEP)Carolina Herrera, Julianne Lwanga, Ming Lee, et al.
Pageof 6